SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue

NCT ID: NCT05230693

Last Updated: 2025-04-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-23

Study Completion Date

2023-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue. The proposed project will evaluate the usability/feasibility of a smartphone-based stress management application for the self-management of sarcoidosis-associated stress and fatigue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis Fatigue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPARC Group

Group Type EXPERIMENTAL

Sarcoidosis Patient Assessment and Resource Companion App

Intervention Type BEHAVIORAL

The first group, called the "SPARC group" will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day

Enhanced Standard Care Control Group

Group Type ACTIVE_COMPARATOR

Enhanced Standard Care

Intervention Type BEHAVIORAL

Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarcoidosis Patient Assessment and Resource Companion App

The first group, called the "SPARC group" will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day

Intervention Type BEHAVIORAL

Enhanced Standard Care

Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sarcoidosis diagnosis based on established criteria
* ≥18 years old
* able to speak, hear, and understand English
* elevated SAF (FAS score ≥22)
* owns smartphone with current data plan
* willingness and ability to use app to engage in Breathing Awareness Meditation (BAM)

Exclusion Criteria

* history of psychotic disorder, bipolar disorder, eating disorder, narcolepsy, cancer diagnosis or treatment in past 12 months
* positive screening for potential major depression (Patient Health Questionnaire depression scale \[PHQ-8; α = .86\] score ≥10)
* untreated sleep apnea (based on home sleep study testing)
* sarcoidosis exacerbation in past 3 months requiring increase in sarcoidosis medications
* \>2 hr travel distance to medical center (to reduce likelihood of no-show for focus groups)
* active substance abuse or binge drinking (\>21 drinks/week )
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

Sponsor Role collaborator

Medical University of South Carolina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

W. Ennis James

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R21EB025525

Identifier Type: NIH

Identifier Source: secondary_id

View Link

00107105

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cell Free DNA in Cardiac Sarcoidosis
NCT03858777 RECRUITING NA
Cardiac Sarcoidosis Randomized Trial
NCT03593759 RECRUITING PHASE3